Intelligence Β· Patent portfolio
Regeneron Ireland Designated Patents
Full USPTO pharma patent portfolio for Regeneron Ireland Designated β grant dates, expiration, and drug cross-links.
- Patents
- 8,292
- Expiring β€24m
- 426
Quick answer
Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months β use filters for patent-cliff planning.
-
US 9629914
Heparosan-based biomaterials and coatings and methods of production and use thereof
granted -
US 9629843
MTOR modulators and uses thereof
granted -
US 9631001
Peptide antagonists of the vasopressin-2 receptor
granted -
US 9630990
Inhibition of pulmonary fibrosis with nutlin-3A and peptides
granted -
US 9630914
Multitarget FAAH and COX inhibitors and therapeutical uses thereof
granted -
US 9629911
Photoreactive regulator of protein function and methods of use thereof
granted -
US 9629848
Compounds that modulate autoimmunity and methods of using the same
granted -
US 9629860
Acyclic nucleoside phosphonate diesters
granted -
US 9632074
Compositions and methods for treating cancer and diseases and conditions responsive to cell growth inhibition
granted -
US 9631188
Human cystathionine Ξ²-synthase variants and methods of production thereof
granted -
US 9631092
Degradable thiol-ene polymers
granted -
US 9622974
Formation of stable submicron peptide or protein particles by thin film freezing
granted -
US 9624472
Production of insulin producing cells
granted -
US 9624484
Engineered primate L-methioninase for therapeutic purposes
granted -
US 9624283
Peptide compounds and methods of production and use thereof
granted -
US 9624303
Single-chain variable fragment anti-CD133 antibodies and uses thereof
granted -
US 9624259
Compositions and methods for scaffold formation
granted -
US 9624255
Carbohydrate-mediated tumor targeting
granted -
US 9624211
Anti-cancer compounds
granted -
US 9623103
Arterivirus protein and expression mechanisms
granted -
US 9623051
Decellularized extracellular matrix
granted -
US 9623040
Immunomodulation by controlling expression levels of microRNAs in dendritic cells
granted -
US 9624304
Antibodies which bind to epithelial membrane protein 2 (EMP2)
granted -
US 9623151
Biomaterials and implants for enhanced cartilage formation, and methods for making and using them
granted -
US 9623035
Triptolide prodrugs
granted -
US 9617512
Derivation of embryonic stem cells and embryo-derived cells
granted -
US 9616047
Inhibitors of beta-catenin in treatment of colorectal cancer
granted -
US 9618521
Sperm-specific cation channel, Catsper2, and uses therefor
granted -
US 9616048
Anti-depression compounds
granted -
US 9617511
Tissue-specific differentiation matrices and uses thereof
granted -
US 9618513
Compositions and methods for detecting and treating colorectal cancer
granted -
US 9616102
Analogs of ShK toxin and their uses in selective inhibition of Kv1.3 potassium channels
granted -
US 9616076
Methods for treating viral infections using hydrogen sulfide donors
granted -
US 9611292
Peptide inhibitors of serotonin 5-HT2c receptors:PTEN interaction
granted -
US 9611266
Compounds and anti-tumor NQO1 substrates
granted -
US 9611258
Dual MEK/PI3K inhibitors and therapeutic methods using the same
granted -
US 9610320
Surgical applications for BMP binding protein
granted -
US 9611330
Compositions and methods for cancer and cancer stem cell detection and elimination
granted -
US 9611456
Progenitor cells from wharton'S jelly of human umbilical cord
granted -
US 9603945
Heparosan polymers and methods of making and using same for the enhancement of therapeutics
granted -
US 9603896
Peptide compounds and methods of production and use thereof
granted -
US 9603824
Compositions and methods for controlling infections
granted -
US 9603829
HSP90 inhibitors with modified toxicity
granted -
US 9606124
Methods of detecting and treating stem-cell containing solid tumors
granted -
US 9605057
Endotrophin neutralization and use thereof
granted -
US 9605042
Compositions and methods related to tauopathy
granted -
US 9605026
Hydrogen-bond surrogate peptides and peptidomimetics for p53 reactivation
granted -
US 9604973
Anti-cancer polyketide compounds
granted
Frequently asked questions
How many patents does Regeneron Ireland Designated have?
8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Regeneron Ireland Designated patents expire?
426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources Β· Patent directory